e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Pulmonary vascular diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model
C. Karaman, M. Karaman, E. S. Ucan, N. Gokmen, D. Gurel, C. Coker, Y. Adali, O. Yilmaz (Izmir, Turkey)
Source:
Annual Congress 2010 - Pulmonary vascular diseases
Session:
Pulmonary vascular diseases
Session type:
Thematic Poster Session
Number:
4489
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Karaman, M. Karaman, E. S. Ucan, N. Gokmen, D. Gurel, C. Coker, Y. Adali, O. Yilmaz (Izmir, Turkey). Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model. Eur Respir J 2010; 36: Suppl. 54, 4489
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on acute decompensated pulmonary hypertension
ERS statement on chronic thromboembolic pulmonary hypertension
COVID-19 and the pulmonary circulation
Related content which might interest you:
Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Reversibility of the monocrotaline pulmonary hypertension rat model
Source: Eur Respir J 2013; 42: 553-556
Year: 2013
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Two rat models of hemolysis-induced pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
The effect of montelukast on the monocrotaline induced pulmonary disease in the wistar rat
Source: Eur Respir J 2004; 24: Suppl. 48, 561s
Year: 2004
Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats
Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Year: 2007
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017
The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
Source: Eur Respir J 2010; 36: 800-807
Year: 2010
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Bosentan fails to prevent the development of pulmonary arterial hypertension in athymic rats exposed to chronic hypoxia
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 365s
Year: 2005
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH).
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Effects of BMPR-II signal transduction in the pulmonary vascular remodeling of monocrotaline induced pulmonary hypertension in rats
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
A novel murine model of severe pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept